Clinical Trial Update: Comparison Study of Standard Care Against Combination of Growth Factors Agents for Low-risk Myelodysplastic Syndromes [Phase 3]

View source ↗

Summary

A completed Phase 3 trial compared standard care with a combination of growth factor agents in patients with low-risk myelodysplastic syndromes. The study statu…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Myelodysplastic Syndromes

Drugs mentioned

• Growth factor agents combination

Snippet

Sponsor: Barts & The London NHS Trust | Conditions: Myelodysplastic Syndrome | Phase 3 | Status: COMPLETED